Wedbush analyst David Nierengarten initiates coverage on Ikena Oncology (NASDAQ:IKNA) with a Outperform rating and announces Price Target of $11.
Wedbush Initiates Coverage On Ikena Oncology With Outperform Rating, Announces Price Target of $11
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.